Clinical Trials | August 28, 2023
Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Reiterates India’s commitment to the BRICS TB Research Network Initiative
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Subscribe To Our Newsletter & Stay Updated
